Fjarde AP Fonden Fourth Swedish National Pension Fund Buys 11,100 Shares of Edwards Lifesciences Corporation $EW

Fjarde AP Fonden Fourth Swedish National Pension Fund lifted its position in shares of Edwards Lifesciences Corporation (NYSE:EW) by 9.4% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 128,766 shares of the medical research company’s stock after purchasing an additional 11,100 shares during the period. Fjarde AP Fonden Fourth Swedish National Pension Fund’s holdings in Edwards Lifesciences were worth $10,071,000 at the end of the most recent quarter.

Several other institutional investors also recently modified their holdings of the company. Teacher Retirement System of Texas increased its stake in shares of Edwards Lifesciences by 90.7% during the 2nd quarter. Teacher Retirement System of Texas now owns 200,964 shares of the medical research company’s stock worth $15,717,000 after purchasing an additional 95,606 shares during the last quarter. Y Intercept Hong Kong Ltd boosted its holdings in shares of Edwards Lifesciences by 534.6% during the 2nd quarter. Y Intercept Hong Kong Ltd now owns 168,378 shares of the medical research company’s stock worth $13,169,000 after buying an additional 141,843 shares during the period. Resonant Capital Advisors LLC boosted its holdings in shares of Edwards Lifesciences by 16.0% during the 2nd quarter. Resonant Capital Advisors LLC now owns 3,886 shares of the medical research company’s stock worth $304,000 after buying an additional 536 shares during the period. Wealthfront Advisers LLC boosted its holdings in shares of Edwards Lifesciences by 10.3% during the 2nd quarter. Wealthfront Advisers LLC now owns 27,579 shares of the medical research company’s stock worth $2,157,000 after buying an additional 2,566 shares during the period. Finally, Hixon Zuercher LLC boosted its holdings in shares of Edwards Lifesciences by 0.7% during the 2nd quarter. Hixon Zuercher LLC now owns 30,731 shares of the medical research company’s stock worth $2,403,000 after buying an additional 226 shares during the period. 79.46% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Edwards Lifesciences

In other news, insider Larry L. Wood sold 8,950 shares of the company’s stock in a transaction that occurred on Monday, August 18th. The shares were sold at an average price of $78.06, for a total transaction of $698,637.00. Following the completion of the sale, the insider owned 206,900 shares of the company’s stock, valued at approximately $16,150,614. This represents a 4.15% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Company insiders own 0.34% of the company’s stock.

Edwards Lifesciences Stock Performance

Shares of Edwards Lifesciences stock opened at $82.26 on Wednesday. The company has a 50 day moving average of $77.49 and a 200-day moving average of $76.65. Edwards Lifesciences Corporation has a 1-year low of $64.89 and a 1-year high of $83.25. The company has a current ratio of 4.68, a quick ratio of 3.87 and a debt-to-equity ratio of 0.06. The company has a market cap of $48.29 billion, a PE ratio of 11.84, a price-to-earnings-growth ratio of 3.88 and a beta of 1.05.

Analyst Ratings Changes

Several analysts recently commented on the stock. Stifel Nicolaus set a $85.00 target price on shares of Edwards Lifesciences and gave the stock a “buy” rating in a report on Monday, September 22nd. Deutsche Bank Aktiengesellschaft lifted their target price on shares of Edwards Lifesciences from $85.00 to $94.00 and gave the stock a “buy” rating in a report on Friday, July 25th. BTIG Research raised shares of Edwards Lifesciences from a “neutral” rating to a “buy” rating and set a $100.00 target price for the company in a report on Tuesday, July 29th. JPMorgan Chase & Co. lifted their target price on shares of Edwards Lifesciences from $80.00 to $85.00 and gave the stock a “neutral” rating in a report on Friday, July 25th. Finally, The Goldman Sachs Group reaffirmed a “buy” rating on shares of Edwards Lifesciences in a report on Friday, July 25th. Three analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating, eight have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $87.33.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.